Cingulate Inc. (NASDAQ:CING) Short Interest Update

Cingulate Inc. (NASDAQ:CINGGet Free Report) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 27,900 shares, a decline of 74.4% from the September 15th total of 108,800 shares. Currently, 1.4% of the shares of the company are sold short. Based on an average daily volume of 3,830,000 shares, the short-interest ratio is presently 0.0 days.

Cingulate Stock Performance

CING traded up $0.39 during trading on Friday, reaching $4.84. 197,070 shares of the company were exchanged, compared to its average volume of 1,285,917. The company’s 50-day moving average is $5.88 and its two-hundred day moving average is $2.51. Cingulate has a 12-month low of $1.80 and a 12-month high of $156.00.

Cingulate (NASDAQ:CINGGet Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($5.47) EPS for the quarter, beating analysts’ consensus estimates of ($5.64) by $0.17. Research analysts forecast that Cingulate will post -12.51 EPS for the current fiscal year.

Institutional Trading of Cingulate

An institutional investor recently bought a new position in Cingulate stock. Armistice Capital LLC bought a new position in Cingulate Inc. (NASDAQ:CINGFree Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 490,000 shares of the company’s stock, valued at approximately $157,000. Armistice Capital LLC owned 6.67% of Cingulate as of its most recent SEC filing. Institutional investors own 41.31% of the company’s stock.

Cingulate Company Profile

(Get Free Report)

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.

See Also

Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.